Endocrinology

Both treatments were well-tolerated with only mild-to-moderate adverse events.

A new study found newly diagnosed type 2 diabetics who develop heart failure had the highest risk of death versus patients with other CVDs or chronic kidney disease.

A weekly growth hormone injection could replace daily injections in children with growth hormone deficiencies.

The COVID-19 pandemic accelerated plans to make changes within their electronic health record system for a trio of Saint Louis University doctors.

Findings of recent research demonstrate an intervention program, Balance after Baby, is promising for decreasing diabetes risk factors in women with recent gestational diabetes.

More than 80% of children and parents found the weekly injections preferable to daily injections.

New research from ARVO 2020 suggests patients with diabetic eye disease can still experiences losses in visual acuity, even with glycemic control.

New research suggests signs a person may be more susceptible to type 2 diabetes later in life are visible in children as young as 8 years old.

The FDA's approval of insulin lispro-aabc injection is based on the results of 2 phase 3 trials—PRONTO-T1D and PRONTO-T2D.

Women with recent gestational diabetes who use the intervention see less retention of weight than those who do not use the intervention.

An analysis of data from 5 PIONEER trials is shedding new light on the impact of oral semaglutide based on background glucose-lowering therapy.

The drug also reduced the risk of myocardial infarction and stroke.

Taking testosterone while enrolled in a lifestyle program reduces glucose levels and risk of type 2 diabetes.

Discussing how advances in care and therapeutic agents have impacted the management of diabetes in 2020.

Todd Hobbs, MD, breaks down research presented at ADA 2020.

Discussing an analysis of retrospective claims data to examine the incidence of herpes zoster in patients with T2DM and how it impacts their diabetes.

Lead investigator of VERTIS-CV discusses results of the phase 3 trial examining ertugliflozin's impact on cardiovascular health.

The prevention of type 2 diabetes is possible and has important clinical benefits.

Not all youth and young adults with diabetes are directly benefiting from the increased availability of diabetes technology, newer therapies, and the use of more aggressive glycemic targets.

An analysis of nearly 8k veterans has found use of metformin was associated with a reduction in PTSD symptoms.

An analysis of the DECLARE-TIMI 58 trial suggests dapagliflozin use could reduce the risk of fast decline in eGFR.

Examining the results of MEX0114, a phase 2 trial evaluating the use of ladarixin in patients with new-onset type 1 diabetes.

An investigator provides an update on the TEDDY study.

Sirimon Reutrakul, MD, discusses what providers should do based on the findings of a new study presented at ADA 2020.

A leader in the field diabetic care, and endocrinology as a whole, Bruce Bode, MD, offers invaluable perspective on the impact of COVID-19 on clinical practice and major trials.

The monitor is approved for children and adults 4 years and older with diabetes.

Results of a new study are diving deeper into potential mediators of the effects of canagliflozin on heart failure and CV death seen in CREDENCE.

A prespecified exploratory analysis suggests the SGLT2 inhibitor reduced the rate of new-onset diabetes by nearly a third.

Chief Medical Officer of Applied Therapeutics discusses a study presented at ADA 2020 examining use of an aldose reductase inhibitor for diabetic complications.